Literature DB >> 16142159

[How can the diagnostic value of head and neck biopsies be increased in Wegener's granulomatosis: a clinicopathologic study of 49 biopsies in 21 patients].

Pierre Raynaud1, Renaud Garrel, Valérie Rigau, Flora Poizat, Patrice Vic, César Cartier, Sophie Rivière, Pierre Baldet, Valérie Costes.   

Abstract

Head and neck biopsies usually have a low diagnostic value in Wegener's granulomatosis (WG). On the basis of 49 biopsies obtained from 21 WG patients at diagnosis from various sites, i.e. nose (29), paranasal sinus (7), oral cavity (4), larynx (4), conjunctiva (3) and external ear (2), we described the suggestive histological features and studied the diagnostic potential of the biopsy size, anaesthesia method (general (GA) or local (LA)), anatomic region of the biopsy, number of sections, and presenting macroscopic manifestations. Associated granulomatous inflammation (scattered giant cells, 28.5% of biopsies; poorly-formed granulomas, 28.5%), necrosis (neutrophilic microabscesses, 16.3%; geographic necrosis, 18.3%), angiitis (leukocytoclastic, 10%; necrotizing, 12%; and granulomatous, 6%) which confirmed the diagnosis were only present in 18.3% of the biopsies (28.5% of the patients). We think it is possible to propose a "WG-compatible" diagnosis when at least one of these histological features is present (24.5% of biopsies, 26% of patients in our study). We found that it was always better to perform biopsies targeted on macroscopic lesions. When there was no lesion, samples from paranasal sinuses obtained under GA had the highest diagnostic value in the head and neck region, whereas 90% of nasal systematic biopsies performed under LA were nonspecific. Moreover, we demonstrated that performing two further sections increased the sensitivity of histological examination by 7%.

Entities:  

Mesh:

Year:  2005        PMID: 16142159     DOI: 10.1016/s0242-6498(05)86171-1

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  6 in total

1.  Histopathological features predictive of a clinical diagnosis of ophthalmic granulomatosis with polyangiitis (GPA).

Authors:  Hazlita Isa; Sue Lightman; Philip J Luthert; Geoffrey E Rose; David H Verity; Simon R J Taylor
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

2.  Clinical aspects of granulomatosis with polyangiitis affecting the head and neck.

Authors:  Andreas Knopf; Adam Chaker; Thomas Stark; Benedikt Hofauer; Tobias Lahmer; Klaus Thürmel; Murat Bas
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-09       Impact factor: 2.503

3.  Increased histopathological yield for granulomatosis with polyangiitis based on nasal endoscopy of suspected active lesions.

Authors:  Olga Beltrán Rodríguez-Cabo; Edgardo Reyes; Jorge Rojas-Serrano; Luis Felipe Flores-Suárez
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-11       Impact factor: 2.503

4.  Orbital pseudotumor can be a localized form of granulomatosis with polyangiitis as revealed by gene expression profiling.

Authors:  James T Rosenbaum; Dongseok Choi; David J Wilson; Hans E Grossniklaus; Christina A Harrington; Cailin H Sibley; Roger A Dailey; John D Ng; Eric A Steele; Craig N Czyz; Jill A Foster; David Tse; Chris Alabiad; Sander Dubovy; Prashant K Parekh; Gerald J Harris; Michael Kazim; Payal J Patel; Valerie A White; Peter J Dolman; Bobby S Korn; Don O Kikkawa; Deepak P Edward; Hind M Alkatan; Hailah al-Hussain; R Patrick Yeatts; Dinesh Selva; Patrick Stauffer; Stephen R Planck
Journal:  Exp Mol Pathol       Date:  2015-07-08       Impact factor: 3.362

5.  Successful endonasal dacryocystorhinostomy in a patient with Wegener's granulomatosis.

Authors:  P Eloy; E Leruth; B Bertrand; P H Rombaux
Journal:  Clin Ophthalmol       Date:  2009-12-29

6.  Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: two case reports and review of literature.

Authors:  David Spoerl; Yves-Marie Pers; Christian Jorgensen
Journal:  Allergy Asthma Clin Immunol       Date:  2012-12-19       Impact factor: 3.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.